Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / EDRN Longitudinal Serum Biorepository

EDRN Longitudinal Serum Biorepository

122
Lynch, HenryCreighton University
Lynch, HenryCreighton University
Other
UNKNOWN
Breast and Gynecologic Cancers Research

Four percent of EDRN Registry mutation carriers developed cancer within a year after beginning follow-up in this registry; within 2 years, 10% had developed cancer. Within 2 years, 17% had developed either a cancer or a pre-malignant lesion (e.g. adenoma). Our goal is to recruit 265 mutation carriers from the EDRN High Risk Registry and Hereditary Cancer Center for the Longitudinal Serum Biorepository (LSB). Based on the cancer rates observed to date in the EDRN Registry, four years of follow-up in a group of this size would be expected to yield 53 invasive and in situ cancers and 37 benign premalignant lesions. All subjects in the serum biorepository (1)have signed consent (2) are counseled carriers (APC, BRCA1, BRCA2, CDH1, CDKN2A, MLH1, MSH2, MSH6) and (3) are enrolled in family studies through CU's Department of Preventive Medicine and/or are enrolled in the EDRN High Risk Registry. Post specimen medical history is collected annually. Serum and plasma are aliquoted for respository storage and stored in labeled cryovials in an ultra low temperature (-86C) freezer. Specimens in the LSB are available for use in EDRN biomarker development and validation studies.

To develop a longitudinal serum biorepository with annual serial samples collected from mutation carriers within the Hereditary Cancer Institute and High Risk Registry for retrospective evaluation of promising biomarkers.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html